Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2020

View Archived Issues

Calpain-2 in common, rare neurodegeneration

Antitoxin vaccine fights S. aureus

Phase I study of DWP-710 approved in Indonesia

Preclinical data presented for anti-CD33 JNJ-67571244 in AML

Novel CLDN18.2-targeted 4-1BB bispecific antibody with potent antitumor activity

BOP1 as new prognostic biomarker in melanoma

AIDS2020: Virtual -- Can state of the ART get to "see you next year"?

Insilico Medicine patents TLR7 and/or TLR8 antagonists

Global Blood Therapeutics divulges SLC40A1 inhibitors

Esteve Pharmaceuticals presents new analgesics

Bicyclerd identifies new IL-17 ligands

Eternity Bioscience patents hSTING receptor agonists

Angion begins phase II study in Brazil with ANG-3777 in patients with COVID-19 pneumonia

NextCure initiates phase I/II trial of LAIR-2 biomimic NC-410

New anti-PD-1 antibody YBL-006 shows high receptor affinity, in vivo activity

DECR1 unveiled as a potential therapeutic target in prostate cancer

Enrollment completed in phase II study of mRNA-1273 for COVID-19

Indivior begins first-in-human study of INDV-2000 for opioid dependence

FDA approves IND for phase I/IIa study of FCR-001 for diffuse systemic sclerosis

Asieris cleared in China to begin global phase III trial of Cevira for high-grade cervical dysplasia

Reverie and Roche establish multi-target collaboration

Constant's TXA-127 to be studied for COVID-19 in phase II trials

Numab begins first-in-human study of NM21-1480 for advanced solid tumors

New phase II study evaluates RUC-4 in patients with STEMI

RefleXion and Telix to study combining technologies for prostate and renal cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...